We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.2B
AUM Growth
+$36.4M
Cap. Flow
+$49.6M
Cap. Flow %
2.25%
Top 10 Hldgs %
26.49%
Holding
159
New
12
Increased
46
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.1M
2
SYK icon
Stryker
SYK
+$19.3M
3
HOLX
Hologic
HOLX
+$13.4M
4
ZBH icon
Zimmer Biomet
ZBH
+$11.4M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.5M
2
DHR icon
Danaher
DHR
+$19.3M
3
MDT icon
Medtronic
MDT
+$19.2M
4
BCR
CR Bard Inc.
BCR
+$18.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Financials 2.8%
3 Consumer Discretionary 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
101
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.9M 0.27%
150,000
– –
ADAP
102
DELISTED
Adaptimmune Therapeutics
ADAP
$5.84M 0.27%
875,000
– –
DVA icon
103
DaVita
DVA
$11.5B
$5.79M 0.26%
+80,100
New +$4.93M
CHRS icon
104
Coherus Oncology
CHRS
$204M
$5.54M 0.25%
629,500
-8,900
-1% -$95.3K
EXEL icon
105
Exelixis
EXEL
$13.3B
$5.32M 0.24%
175,000
– –
MRUS
106
DELISTED
Merus
MRUS
$5.28M 0.24%
271,952
-3,048
-1% -$51.6K
RARX
107
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$5.1M 0.23%
600,000
– –
HRTX icon
108
Heron Therapeutics
HRTX
$91.2M
$4.53M 0.21%
+250,000
New +$4.08M
CRVS icon
109
Corvus Pharmaceuticals
CRVS
$1.15B
$4.38M 0.2%
422,600
– –
MGNX icon
110
MacroGenics
MGNX
$255M
$4.28M 0.19%
225,000
– –
GTHX
111
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.26M 0.19%
214,500
-25,500
-11% -$548K
CBAY
112
DELISTED
Cymabay Therapeutics
CBAY
$4.14M 0.19%
450,000
– –
BCRX icon
113
BioCryst Pharmaceuticals
BCRX
$2.39B
$3.99M 0.18%
812,500
+362,500
+81% +$1.76M
KA
114
DELISTED
Kineta, Inc. Common Stock
KA
$3.94M 0.18%
4,821
+1,607
+50% +$616K
NBRV
115
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.74M 0.17%
2,500
– –
MYOV
116
DELISTED
Myovant Sciences Ltd.
MYOV
$3.73M 0.17%
295,100
– –
IRWD icon
117
Ironwood Pharmaceuticals
IRWD
$711M
$3.37M 0.15%
268,650
+29,850
+13% +$390K
MRTX
118
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.29M 0.15%
+180,000
New +$2.79M
DVAX
119
DELISTED
Dynavax Technologies
DVAX
$3.27M 0.15%
175,000
+10,000
+6% +$201K
KDNY
120
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.11M 0.14%
83,000
– –
BMY icon
121
Bristol-Myers Squibb
BMY
$132B
$3.06M 0.14%
50,000
– –
AGN.PRA
122
DELISTED
Allergan plc
AGN.PRA
$2.93M 0.13%
5,000
– –
SYRE icon
123
Spyre Therapeutics
SYRE
$9.19B
$2.83M 0.13%
20,964
– –
ITCI
124
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.71M 0.12%
187,500
– –
NVAX icon
125
Novavax
NVAX
$1.32B
$2.48M 0.11%
100,000
+59,000
+144% +$1.44M
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

Rock Springs Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rock Springs Capital Management held 159 positions worth $2.2B, up 1.7% from $2.17B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q4 2017 filing shows 12 new, 46 increased, 21 reduced and 14 closed positions. Its largest new stake was Teleflex: 91,750 shares worth $22.8M. The largest sale was Aetna Inc, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2017 buy was Teleflex: 91,750 shares worth $22.8M.
  • Rock Springs Capital Management added most to Zimmer Biomet in Q4 2017, an estimated $11.4M increase.
  • Rock Springs Capital Management's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $27.5M.
  • Rock Springs Capital Management fully exited Danaher in Q4 2017, selling an estimated $19.3M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.2B portfolio in Q4 2017.
  • Rock Springs Capital Management opened 12 new positions and closed 14 in Q4 2017.
  • Rock Springs Capital Management's portfolio value rose 1.7% quarter-over-quarter to $2.2B.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.